Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 6721-6730 Newer>

The Motley Fool April 8, 2005 Rick Aristotle Munarriz	The Fool's Look Ahead Stocks that will be making financial announcments this week: Circuit City, Travelzoo, etc.
The Motley Fool April 8, 2005 Rick Aristotle Munarriz	Home Stocks, Sweet Home Stocks Defying gravity for another quarter, homebuilders continue to produce healthy results.
The Motley Fool April 7, 2005 W.D. Crotty	WD-40's Squeaky Wheel WD-40's second-quarter net income falls 15.5%.
The Motley Fool April 7, 2005 Stephen D. Simpson	A New China Yuchai? An agreement between China Yuchai and Coomber to settle their dispute over control of Chinese diesel engine maker Yuchai looks promising, but investors should be wary of the risk that the deal might fall apart.
The Motley Fool April 7, 2005 Steven Mallas	Video Game Stocks Here to Play With the new consoles on the way, shouldn't you be thinking about video game companies for your portfolio?
The Motley Fool April 7, 2005 Jeremy MacNealy	Bed Bath & Be-Yawn It has been a flat 12 months for the retailer's stock, despite record results. Is the market too demanding?
The Motley Fool April 7, 2005 Bill Mann	AIG: What's the Buzz? Things keep coming up out of the woodwork at AIG. They're probably not fatal, but there should be no question that hidden problems remain, and they are of unknown size and tenor.
The Motley Fool April 7, 2005 Nathan Slaughter	Is Topps at a Bottom? The confectioner and trading-card company posts fourth straight year of down sales. However, top line growth is in the forecast this year, and each share comes with around $2.60 in cash inside.
The Motley Fool April 7, 2005 Tim Beyers	TiVo Tunes In Patents The DVR maker spends to build a better TV portal. It's unclear whether ads will ever have an impact on TiVo's revenues. But I wouldn't underestimate the possibility. Investors, take note.
The Motley Fool April 7, 2005 Brian Gorman	Merck Soldiers On The drug company's experimental HPV treatment has significant potential. Investors should not overlook the company's positive developments.
<Older 6721-6730 Newer> Return to current articles.